Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal to manufacture... – The protein is isolated or extracted from milk
Reexamination Certificate
2004-05-14
2009-06-09
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal to manufacture...
The protein is isolated or extracted from milk
C514S012200
Reexamination Certificate
active
07544853
ABSTRACT:
The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
REFERENCES:
patent: 7067713 (2006-06-01), Nuijens et al.
patent: 2005/0223416 (2005-10-01), Nuijens et al.
patent: 0586909 (1994-03-01), None
patent: 2601034 (1988-01-01), None
patent: WO 91/06650 (1991-05-01), None
patent: WO 92/22320 (1992-12-01), None
patent: WO 96/03051 (1996-02-01), None
patent: WO 01/57079 (2001-08-01), None
Bos et al. Expression of Recombinant C1-Inhibitor in the Methylotrophic. 2002, International Immunopharm., vol. 2, No. 9, pp. 1330, abs. 11.
Akita, N., et al., “The effect of C 1 esterase inhibitor on ischemia: reperfusion injury in the rat brain,”No To Shinkei, vol. 53(7), pp. 641-644 (2001) [Article in Japanese]English Abstract only.
Bork, et al., “Long-Term Prophylaxis with C1-inhibitor (C1 INH) Concentrate in Patients with Recurrent Angioedema Caused by Hereditary and Acquired C1-Inhibitor Deficiency,”J. Allergy Clinical Immunology, vol. 83, pp. 677-682 (1989).
Bos, I.G.A., et al., “Recombinant human C1-inhibitor produced inPichia pastorishas the same inhibitory capacity as plasma C1-inhibitor,”Biochimica et Biophysica Acta, vol. 1648, pp. 75-83 (2003).
Carter P. et al.,Euro J. Biochem. 173;163, (1988).
Chu, L. and D.K. Robinson, “Industrial choices for protein production by large-scale cell culture,”Current Opinion in Biotechnology, vol. 12, pp. 180-187 (2001).
Cicardi, M. et al.,Immunobiol. 199:366, (1998).
Davis A.E.,Ann. Rev. Immunol. 6:595-628 (1988).
De Filippi, F et al.,Transfusion38:307, (1998).
Eldering, E. et al., “Expression of functional human C1 inhibitor in COS cells,”J. Biol. Chem. vol. 263(24), pp. 11776-11779 (1988).
Gonçalves, M.A.F.V, “A concise peer into the background, initial thoughts and practices in human gene therapy,”Bioessays, vol. 27, pp. 506-517 (2005).
Hack, C. et al.,LANCET, 339:8789 378, (1992).
Houdebine, L.M., “Transgenic Animal Bioreactor,”Transgenic Res., vol. 9 (4-5), pp. 305-320 (2000).
Koles, K., et al., “Influence of Lactation Parameters on the N-Glycosylation of Recombinant Human C1 Inhibitor Isolated from the Milk of Transgenic Rabbits,”Glycobiology, vol. 14(11), pp. 979-986 (2004).
Lamark, T., et al., “Expression of active human C1 inhibitor in serpin domain ofEscherichia coli,”Protein Expression and Purification, vol. 22, pp. 349-358 (2001).
Marasini, B., et al., “Treatment of hereditary angioedema,”Klin Wochenschr., vol. 56(16), pp. 819-823 (1978) [Article in German]English Abstract only.
Rai, M. and H. Padh, “Expression of systems for production of heterologous proteins,”Current Science, vol. 80(9,10), pp. 1121-1128 (2001).
Schapira, M. et al.,Complement2:111 (1985).
Shoenberger. O.L., “Characterization of carbohydrate chains of C1-inhibitor and desialylated C1-inhibitor,”FEBS, vol. 314, pp. 430-434 (1992).
Wolff, M.W., et al., “Expression of C1 esterase inhibitor by the baculovirus expression vector system: Preparation, purification and characterization,”Protein Expression and Purification, vol. 22, pp. 414-421 (2001).
Wurm, F.M., “Production of recombinant protein therapeutics in cultivated mammalian cells,”Nature Biotechnology, vol. 22(11), pp. 1393-1398 (2004).
Zurlo J. et al.Fertility and Sterility54:64, (1990).
Crouch Deborah
Pharming Intellectual Property B.V.
Townsend and Townsend / and Crew LLP
LandOfFree
C1 inhibitor with short half-life transient treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C1 inhibitor with short half-life transient treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C1 inhibitor with short half-life transient treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4121762